Unaudited Financial Result for Quarter and Nine months ended on December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ambar Protein Industries reported revenue from operations of Rs 12,191.97 lakhs for Q3 FY26, up from Rs 11,181.71 lakhs in Q3 FY25 (a ~9% YoY rise). For the nine months ended December 2025, revenue grew to Rs 35,385.63 lakhs from Rs 29,381.43 lakhs in the same period last year, a healthy ~20.4% YoY increase. However, net profit fell sharply: Q3 PAT dropped to Rs 181.43 lakhs (vs Rs 282.42 lakhs, down ~36% YoY), and 9M PAT declined to Rs 456.25 lakhs (vs Rs 716.55 lakhs, down ~36.3% YoY). Basic EPS for 9M stood at Rs 7.94 versus Rs 12.46 last year. The company operates in a single segment (manufacturing and selling of edible oil), and the auditor issued a clean limited review report with no qualifications or concerns flagged.
Mixed signals for shareholders: strong top-line growth is being eroded by rising raw material costs (cost of materials rose from 91.5% to 95.1% of revenue), squeezing margins and profits. While the business is still profitable, the sharp decline in earnings despite revenue growth may weigh on near-term stock sentiment, though the clean audit report provides some comfort.